miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer

• Published in: Chinese medical journal Vol. 126; no. 23; pp. 4435 - 4439
• Main Authors: Gu, Yan-fei, Zhang, Hui, Su, Dan, Mo, Min-li, Song, Pan, Zhang, Fang, Zhang, Shu-cai
• Format: Journal Article
• Language: English
• Published: China Division of Life & Health Sciences, Graduate School at Shenzhen,Tsinghua University, Center for Biotech & Biomedicine 05.12.2013; Shenzhen Key Lab of Gene & Antibody Therapy, Shenzhen, Guangdong 518055, China; Department of Oncology , Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing 101149, China%Department of Pathology , Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing 101149, China%School of Life Sciences, Tsinghua University, Beijing 100084, China%Beijing ACCB Biotech Ltd., Beijing 100094, China%Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang 314006, China
• Subjects: Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Humans; Kaplan-Meier Estimate; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; microRNA; MicroRNAs - genetics; Protein Kinase Inhibitors - therapeutic use; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; 中和; 治疗; 肿瘤发生; 表皮生长因子受体; 酪氨酸激酶抑制剂; 非小细胞肺癌; 预测因子; non-small cell lung cancer; microRNA; tyrosine kinase inhibitor; epidermal growth factor receptor
• ISSN: 0366-6999; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.20131112

Background Aberrantly expressed microRNAs are a hallmark of cancer,and microRNA expression profiling is associated with tumor progression and response to chemotherapy,suggesting their potential application as prognostic and predictive biomarkers.The role of microRNAs in lung cancer remains elusive.It has been recently reported that epidermal growth factor receptor （EGFR） and hepatocyte growth factor receptor （MET） tyrosine kinase can regulate expression of specific microRNAs including miR-30b,miR-30c,miR-221,miR-222,miR-103 and miR-203,and induce tumorigenesis and gefitinib resistance in lung cancers.We intend to study the role of miR-30b and miR-30c expression in predicting response to tyrosine kinase inhibitors （TKIs） in non-small cell lung cancer （NSCLC）.Methods We have therefore retrospectively examined expression of miR-30b miR-30c in 41 formalin fixed paraffin embedded tissue samples from NSCLC patients when TKIs were used as first line therapy.Results We found a significant correlation between expression of miR-30b and miR-30c.Furthermore,miR-30b and miR-30c expression correlated with short-term response.Kaplan-Meier analysis further revealed that the expression of miR-30b and miR-30c predicted progression free survival and the overall survival rate in the examined cohort.Conclusion Our study identified miR-30b and miR-30c as useful prognostic predictors in NSCLC patients who underwent first line treatment with TKIs.